Skip to main content
. 2016 Oct 19;8(1):757–768. doi: 10.18632/oncotarget.12748

Figure 1. Binding of ALOS4-FITC conjugate to WM-266-4 human metastatic melanoma cells in vitro.

Figure 1

A. Expression of integrin αvβ3 in WM-266-4 cells was evaluated by FACS analysis using FITC-conjugated integrin αvβ3 antibody (black-control cells w/o an antibody, purple-cells incubated with FITC-conjugated integrin αvβ3 antibody). B. Binding of ALOS4-FITC to the WM-266-4 cells at concentrations of 1μM (blue), 5μM (red) and 20μM (green). Auto-fluorescence of the cells is marked by a black line. C. Binding of 10 μM of ALOS4-FITC in the presence of the ''scrambled” peptide P1 at concentrations of 1μM (blue), 5μM (red) and 20μM (green). Auto-fluorescence of the cells is marked by a black line. D. Fluorescence of live WM-266-4 cells following incubation with 10 μM of FITC or ALOS4-FITC. Scale bar: 100 μm.